Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tardive tremor.

M Stacy1, J Jankovic

  • 1Department of Neurology, Baylor College of Medicine, Houston, Texas 77030.

Movement Disorders : Official Journal of the Movement Disorder Society
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Tardive tremor, a new hyperkinetic movement disorder, is linked to neuroleptic medication. This tremor improves with tetrabenazine, a dopamine-depleting drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biliary Enterocytozoon bieneusi infection in a dog under immunomodulatory therapy.

The Journal of small animal practice·2023
Same author

Hyperkinetic movement disorders in congenital disorders of glycosylation.

European journal of neurology·2019
Same author

McLeod syndrome: Five new pedigrees with novel mutations.

Parkinsonism & related disorders·2019
Same author

Association between non-communicable disease multimorbidity and health care utilization in a middle-income country: population-based study.

Public health·2018
Same author

Treatment options for chorea.

Expert review of neurotherapeutics·2017
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same journal

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Putamen Structural-Functional Decoupling as an Early-Stage Candidate Imaging Marker for Motor Severity in Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Melanopsin-Mediated Post-Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

The LRRK2 G2385R Exonic Variant and Multiple System Atrophy: Findings from the Japan MSA Registry.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Area of Science:

  • Neuroscience
  • Movement Disorders
  • Pharmacology

Background:

  • Neuroleptic medications (dopamine receptor blocking drugs) are known to cause various hyperkinetic movement disorders.
  • However, tardive tremor has not been previously documented as a potential side effect.

Observation:

  • Five patients developed tremor after chronic neuroleptic treatment.
  • The tremor persisted after drug withdrawal and showed improvement with tetrabenazine.
  • This involuntary movement (3-5 Hz) occurred at rest, during posture maintenance, and goal-directed actions.

Findings:

  • The tremor was associated with other tardive movement disorders like akathisia, chorea, dystonia, myoclonus, and stereotypy.
  • No family history or alternative explanations for tremor were identified in these patients.

Related Experiment Videos

  • This presentation suggests a distinct clinical entity, termed tardive tremor.

    • Implications:

    • Tardive tremor is a newly identified neuroleptic-induced movement disorder.
    • Dopamine depletion via tetrabenazine may be an effective treatment strategy.
    • Further research is warranted to understand the pathophysiology and prevalence of tardive tremor.